PubMed Health⌕ Search

PubMed · 12134540

[Hypertension and endothelial dysfunction].

Abstract

Endothelium; effective in vascular tonus, blood tension, blood flow and coagulation system is the biggest endocrine organ with 1800 gr. weight in human body. The endothelium releases nitric oxide, which maintains vascular integrity. In endothelial dysfunction the balance between releasing vasodilatatory and vasoconstrictory factors is changed. In the presence of essential hypertension defection in endothelium-dependent vasodilation and increasing sensitivity to vasoconstrictors could increase vascular resistance. Although some beneficial results with angiotensin converting enzyme inhibitors, carvedilol, angiotensin-II and endothelin receptor antagonists were reported in patients with endothelial dysfunction the effectiveness of these drugs is still debate. Also the decreasing of arterial pressure was not always shown to be parallel to the restoration of endothelial dysfunction. In the future according to genetic studies, the increased use of nitric oxide releasing genes therapy will have a more effective role in regression of endothelial dysfunction.

Explore related subjects

Keep this discovery

Explore connections, maps & timelines

BibTeXRIS

Mehdi Zoghi, Istemi Nalbantgil. 2002. [Hypertension and endothelial dysfunction].. https://pubmed.ncbi.nlm.nih.gov/12134540/

Cite the original work for its findings. Save a collection to share your selection of sources.

KEEP EXPLORING

Related citations

Simultaneous determination of losartan and EXP3174 in human plasma and urine utilizing liquid chromatography/tandem mass spectrometry.

Losartan is an orally active angiotensin II receptor antagonist indicated for the treatment of hypertension. EXP3174 is an active metabolite, which contributes to the overall activity of losartan. Analytical methods for the simultaneous determination of losartan and its active metabolite EXP3174 in human plasma and urine with limited plasma sample size have been developed and validated to support a pediatric clinical program. In both methods, analytes are extracted from the matrixes by liquid-liquid extraction and separated using reverse phase high-performance liquid chromatography (HPLC). A tandem mass spectrometer (MS/MS) with a Turbo ionspray (TIS) interface in multiple-reaction-monitoring (MRM) mode is used for detection of the analytes in both methods. The plasma method has a lower limit of quantitation (LOQ) of 1 ng/ml with a linearity range of 1-500 ng/ml for losartan and EXP3174 using 100 microl of plasma. For the urine method, the LOQ for both losartan and EXP3174 is 2 ng/ml using 0.5 ml of urine, and the linearity range for both analytes is 2-1000 ng/ml. Validation procedures have proven that both methods are robust, accurate, and reproducible. Both methods have been used to assay clinical samples and provided satisfactory results.

Antihypertensive Agents↗

[Cardiovascular disease in those aged 55 years and over controlled with a combined pill against 4 risk factors: some brief comments].

It was recently proposed that people with a high absolute cardiovascular risk, for example those aged 55 years and over, might considerably benefit from a combined pill that includes proven treatments such as a statins, antihypertensives, antiplatelet therapy and folic acid. Although conceptually attractive, certain negative effects need to be considered. A strategy to treat the population aged 55 years and over might yield large benefits in high-risk patients with fairly normal values for risk factors that are currently often left untreated. It may, however, also lead to the undertreatment of patients with abnormally high values of individual risk factors and to the overtreatment of low-risk patients. In these low-risk patients, the side effects of aspirin and blood-pressure lowering treatment might outweigh the benefits. Due to the high costs and also the availability of generic drugs, it is difficult to envision trials that will address these issues. Therefore, the acceptance and implementation of this intriguing concept by health authorities and insurance companies remains doubtful.

Antihypertensive Agents↗